Rabia Gurses Ozden - Feb 3, 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Medical Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
Stock symbol
OCUL
Transactions as of
Feb 3, 2024
Transactions value $
$30,842
Form type
4
Date filed
2/6/2024, 06:32 PM
Previous filing
Feb 2, 2024
Next filing
Jun 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +66.6K +71.83% $0.00 159K Feb 3, 2024 Direct F1
transaction OCUL Common Stock Sale $30.8K +6.35K +4.33% $4.86 153K Feb 5, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +200K $0.00 200K Feb 3, 2024 Common Stock 200K $5.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 3, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2024. The sales do not represent a discretionary trade by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.94, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.